ivosidenib — United Healthcare
myelodysplastic syndrome (MDS)
Initial criteria
- Diagnosis of myelodysplastic syndrome (MDS)
- Disease is relapsed or refractory
- Presence of IDH1 mutation
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Tibsovo therapy
Approval duration
12 months